HOME > TOP STORIES
TOP STORIES
-
REGULATORY LDP OKs Economic, Fiscal Policy Guidelines, but Wording on Reference Pricing Could Change
June 26, 2015
-
REGULATORY HTAs Likely to Be Used for Re-Pricing of Listed Medicines
June 25, 2015
-
REGULATORY Drug Pricing Tomorrow: Ex-Chuikyo Chair Urges Pharma to Look at How to Refine Premium, Not Permanent Introduction
June 25, 2015
-
REGULATORY LDP Begins Intraparty Deliberations on Economic, Fiscal Blueprint
June 24, 2015
-
REGULATORY 80% Generic Share “at Early Date,” Essential Drug Supplies Join Draft Fiscal Policy Blueprint
June 23, 2015
-
REGULATORY AMED’s Screening Consortium “Won’t Harm Companies”: Official
June 22, 2015
-
BUSINESS 30 Companies Obtain Listing for Plavix Generics
June 19, 2015
-
REGULATORY Ryukaikon to Push Single-Product, Single-Price Deals in New Proposal Due Out Summer
June 18, 2015
-
REGULATORY Govt Deregulation Panel Calls for Revisiting 14-Day Prescription Limit
June 17, 2015
-
ACADEMIA MHLW Official Restates Difficulty of Moving Up Timeline to Attain 80% Generic Share
June 16, 2015
-
ORGANIZATION Industry Calls for Definition of “Basic Drugs”: FPMAJ Committee
June 15, 2015
-
REGULATORY Takeda Slapped with Business Improvement Order over CASE-J
June 12, 2015
-
REGULATORY Accession Requirements for ICH Assembly Hammered Out at Fukuoka Confab
June 12, 2015
-
ORGANIZATION EFPIA Japan Chief Frets Negative Market Growth amid Pressure on Drug Costs
June 11, 2015
-
BUSINESS Novartis Japan Chief Vows All-Out Effort to Regain Trust
June 10, 2015
-
BUSINESS Highlights of FY2014 Earnings - Part 5: Lackluster 1% Sales Growth Likely in FY2015
June 10, 2015
-
REGULATORY LDP Eyes Filing of 15 Sakigake Designated Products by FY2018
June 9, 2015
-
ORGANIZATION Industry, Govt, Academia Should Discuss Challenges Facing Biosimilars: Prof. Kurokawa
June 9, 2015
-
BUSINESS Highlights of FY2014 Earnings - Part 4: Overseas Sales Top 4 Trillion Yen; Fate of Drug Makers Will Depend on New Global Products
June 9, 2015
-
REGULATORY Roughly 60 Products Submitted as Candidates for Review under Sakigake Designation System
June 8, 2015
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
